Earnings Call Summary | Yield10 Bioscience(YTEN.US) Q4 2023 Earnings Conference
Earnings Call Summary | Yield10 Bioscience(YTEN.US) Q4 2023 Earnings Conference
The following is a summary of the Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript:
以下是Yield10 Bioscience, Inc.（YTEN）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Yield10 Bioscience reported a net loss of $3.3 million or $0.27 per share for Q4 2023, the same as the Q4 of the previous year.
R&D expenses were $2 million during Q4 2023, and payments from seed and harvested grain shipments reduced their R&D expenses by $110,000.
G&A expenses stayed consistent at $1.4 million for both Q4 2023 and 2022.
For the entire year of 2023, the company reported a net loss of $14.5 million or $1.82 per share, compared to a net loss of $13.6 million or $2.76 per share in 2022. R&D expenses for 2023 were slightly up from the previous year, while G&A expenses remained the same.
Yield10 Bioscience報告稱，2023年第四季度淨虧損330萬美元，合每股虧損0.27美元，與去年第四季度持平。
2023年第四季度的研發費用爲200萬美元，種子和收穫穀物的運輸付款使他們的研發費用減少了11萬美元。
2023年第四季度和2022年第四季度的併購支出均穩定在140萬美元。
2023年全年，該公司報告的淨虧損爲1,450萬美元，合每股虧損1.82美元，而2022年的淨虧損爲1,360萬美元，合每股虧損2.76美元。2023年的研發費用比上年略有增加，而併購支出保持不變。
Business Progress:
業務進展：
Yield10 is progressing in commercializing sustainable products using oilseed Camelina, focusing on omega-3 fatty acids and low carbon biofuels.
They revised their biofuel strategy to provide R&D services to third parties. This resulted in their first license agreement with Vision Bioenergy Oilseeds, an arm of Shell Oil.
The company cleared all major regulatory hurdles to grow genetically engineered Camelina in the US and plans to begin commercial production of their EPA and EPA DHA oil products in 2025/2026.
The focus is not just on company growth, but also addressing market gaps in aquaculture, human nutrition, and pharmaceuticals, and the energy sector.
Plans for 2024 include delivering the first omega-3 product samples and gaining regulatory approval for oil use in Chile's aquafeed.
Yield10 is also working towards scaling their production and pursuing partnerships for offtake agreements of omega-3 oil.
Yield10在使用油籽Camelina的可持續產品商業化方面正在取得進展，重點是omega-3脂肪酸和低碳生物燃料。
他們修改了生物燃料戰略，向第三方提供研發服務。這促使他們與殼牌石油旗下的Vision Bioenergy Oilseeds簽訂了第一份許可協議。
該公司清除了在美國種植轉基因Camelina的所有主要監管障礙，並計劃在2025/2026年開始商業化生產其EPA和EPA DHA油產品。
重點不僅是公司的發展，還包括解決水產養殖、人類營養和製藥以及能源領域的市場空白。
2024年的計劃包括交付首批omega-3產品樣品，並獲得監管部門批准智利水產飼料中的石油用途。
Yield10還努力擴大產量，並尋求建立合作伙伴關係，以達成歐米茄-3石油的承購協議。
More details: Yield10 Bioscience IR
更多詳情： Yield10 生物科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。